RT Journal Article
SR Electronic
T1 Long-term noninvasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4349
DO 10.1183/13993003.congress-2020.4349
VO 56
IS suppl 64
A1 Mª Ángeles Sanchez Quiroga
A1 Juan Fernando Masa Jiménez
A1 Ivan Benitez
A1 Javier Gómez De Terreros
A1 Jaime Corral
A1 Auxiliadora Romero
A1 Candela Caballero Eraso
A1 Maria Luz Alonso Alvarez
A1 Estrella Ordax
A1 Teresa Gomez Garcia
A1 Soledad Lopez Martin
A1 Jose Maria Marin
A1 Sergi Marti
A1 Trinidad Diaz Cambriles
A1 Eusebi Chiner
A1 Carlos Egea
A1 Javier Barca
A1 Francisco Javier Vazquez Polo
A1 Miguel Angel Negrin
A1 Maria Martel Escobar
A1 Ferran Barbe
A1 Babak Mohklesi
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/4349.abstract
AB Rationale: Noninvasive ventilation (NIV) is an effective treatment in obesity hypoventilation syndrome (OHS) with severe obstructive sleep apnoea (OSA) but there is paucity of evidence in OHS patients without severe OSA phenotype.Methods: In this multicentre (16 sites in Spain), open-label parallel group clinical trial, we randomly assigned 98 stable ambulatory patients with untreated OHS and apnoea-hypopnoea index <30 events/hour to NIV or lifestyle modification (control). The primary end point was hospitalization days/year. The analysis was performed according to the intention-to-treat and per-protocol principles.Results: 49 patients were randomised in each group and 48 patients were analysed in each one of them. During a median [IQR] follow-up of 4.98 [2.98; 6.62] years, mean (SD) hospitalization days/year was 2.60 (5.31) in the control group and 2.71 (4.52) in the NIV group [adjusted rate ratio (95% CI) 1.07 (0.44; 2.59) (p = 0.882)]. Cardiovascular events occurred in 11 (23%) participants in the control group and 10 (21%) in the NIV group (hazard ratio (95% CI) 0.96 (0.40;2.30), p=0.927). Similar results were observed in the per-protocol analysis [rate ratio (95% CI) 1.21 (0.43;3.41) (p=0.717)]. Death occurred in 9 (19%) participants in both arms (adjusted hazard ratio (95% CI) 1.07 (0.41;2.82), p=0.893). Similar results were found in the per-protocol analysis [rate ratio (95% CI) 1.38 (0.50;3.79) (p=0.529)].Conclusion: In stable ambulatory patients with OHS without severe OSA, NIV and lifestyle modification had similar long-term hospitalization days-year. Larger studies are necessary to better determine the long-term benefit of NIV in this subgroup of OHS.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4349.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).